Vutrisiran therapy leads to significant improvements in biventricular systolic function and reductions in left ventricular mass in patients with transthyretin amyloid cardiomyopathy (ATTR-CM).
Cardiovascular magnetic resonance (CMR) imaging with extracellular volume (ECV) mapping enables sensitive, noninvasive tracking of cardiac amyloid burden and treatment-related regression.
Post hoc analysis of the UK HELIOS-B cohort demonstrates that vutrisiran associates with amyloid regression in a subset of patients and markedly reduces amyloid progression compared to placebo over three years.
Echocardiographic secondary outcomes corroborate structural and functional cardiac benefits, underscoring vutrisiran’s impact on clinical outcomes.
Background
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
